Risk assessment for drug degradation products using physiologically-based pharmacokinetic models
Degradation product toxicity is a critical quality issue for a small group of useful drug products--e.g. lidocaine, isoniazid, chlorhexidine, gabapentin. In the traditional risk assessment approaches, a no-observed-adverse-effect level (NOAEL) derived...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | English |
| Published: |
University of Iowa
2014
|
| Subjects: | |
| Online Access: | https://ir.uiowa.edu/etd/1993 https://ir.uiowa.edu/cgi/viewcontent.cgi?article=6330&context=etd |